CN113474363A - 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 - Google Patents

用于降低体重和/或减少食物摄取量的gdf15类似物和方法 Download PDF

Info

Publication number
CN113474363A
CN113474363A CN201980089716.4A CN201980089716A CN113474363A CN 113474363 A CN113474363 A CN 113474363A CN 201980089716 A CN201980089716 A CN 201980089716A CN 113474363 A CN113474363 A CN 113474363A
Authority
CN
China
Prior art keywords
dose
administered
study
fusion protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089716.4A
Other languages
English (en)
Chinese (zh)
Inventor
郑松茂
H·金科
R·赫曼
E·法布里尼
V·斯托贾诺维奇-苏苏里奇
P·罗滕贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202511010324.8A priority Critical patent/CN121818901A/zh
Publication of CN113474363A publication Critical patent/CN113474363A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201980089716.4A 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 Pending CN113474363A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511010324.8A CN121818901A (zh) 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511010324.8A Division CN121818901A (zh) 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Publications (1)

Publication Number Publication Date
CN113474363A true CN113474363A (zh) 2021-10-01

Family

ID=70773869

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980089716.4A Pending CN113474363A (zh) 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
CN202511010324.8A Pending CN121818901A (zh) 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511010324.8A Pending CN121818901A (zh) 2018-11-20 2019-11-19 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Country Status (15)

Country Link
US (1) US20220315633A1 (https=)
EP (1) EP3883960A4 (https=)
JP (2) JP2022513098A (https=)
KR (1) KR20210094584A (https=)
CN (2) CN113474363A (https=)
AU (2) AU2019383019A1 (https=)
BR (1) BR112021009225A2 (https=)
CA (1) CA3120236A1 (https=)
EA (1) EA202191424A1 (https=)
IL (1) IL283189A (https=)
JO (1) JOP20210111A1 (https=)
MX (1) MX2021005908A (https=)
PH (1) PH12021551119A1 (https=)
SG (1) SG11202104952PA (https=)
WO (1) WO2020104948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327560A1 (en) * 2016-05-10 2017-11-16 Janssen Biotech, Inc. Gdf15 fusion proteins and uses thereof
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2020084496A1 (en) * 2018-10-22 2020-04-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US20170327560A1 (en) * 2016-05-10 2017-11-16 Janssen Biotech, Inc. Gdf15 fusion proteins and uses thereof
WO2020084496A1 (en) * 2018-10-22 2020-04-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Also Published As

Publication number Publication date
JOP20210111A1 (ar) 2021-05-19
CN121818901A (zh) 2026-04-10
BR112021009225A2 (pt) 2021-10-05
AU2019383019A1 (en) 2021-06-03
KR20210094584A (ko) 2021-07-29
JP2022513098A (ja) 2022-02-07
EP3883960A4 (en) 2022-11-09
WO2020104948A1 (en) 2020-05-28
MX2021005908A (es) 2021-09-08
PH12021551119A1 (en) 2021-11-22
AU2025202337A1 (en) 2025-04-24
US20220315633A1 (en) 2022-10-06
JP2025081388A (ja) 2025-05-27
EA202191424A1 (ru) 2021-08-24
IL283189A (en) 2021-06-30
EP3883960A1 (en) 2021-09-29
SG11202104952PA (en) 2021-06-29
CA3120236A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CN113272326B (zh) 治疗嗜中性病症的方法
JP2025081388A (ja) 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法
US20240358704A1 (en) Combined administration
US20260070997A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
JP2023549455A (ja) 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
KR20250051760A (ko) Actrii 항체 고정 단위 용량 치료
EA006881B1 (ru) ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ
CN119174811A (zh) Hmmr配体的用途
CN114159552A (zh) 使用长效epo配制物治疗贫血的方法
US20240424055A1 (en) Administration of c5-binding proteins
KR102703936B1 (ko) 과도한 유리형 light를 포함하는 방법 및 치료
WO2023245543A1 (en) Uses of fgf21 fusion proteins
WO2025120567A1 (en) Method of treatment of asthma
Moretz Orphan Drug Evaluation: Myalept®(metreleptin) subcutaneous injection
EP4716545A1 (en) Treatment of adults with overweight or obesity with or without weight-related comorbidities
EP4634225A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211001